theme08のラベル

We aim to maximize the potential of the small-molecule compounds we have previously obtained. To achieve this goal, we invite proposals addressing the discovery of new target diseases or conditions for these compounds.

Pharmaceuticals Research Center
Laboratory for Medicinal Chemistry

theme08のメイン画像

Creating for Tomorrow


“ Identification of Novel Drug Indications ”

Message 

CMC研究部 主幹研究員 画像

Yasuhiro Wada, PhD

Principal Scientist
Laboratory for Medicinal Chemistry

We created the following compounds by making full use of our preclinical lead optimization technologies:

  • ・Secreted frizzled-related protein 1 (sFRP1) inhibitors
  • ・Transient receptor potential ankyrin 1 (TRPA1) inhibitors

During the period of our collaboration, the compounds developed at Asahi Kasei Pharma will be provided at no cost. Working together with our partners, we will pursue our commitment of “Creating for Tomorrow” by identifying new target diseases or conditions for these compounds. We welcome your constructive suggestions to ease without delay patients' suffering worldwide.

Recruitment theme 

8.1 Discovery of new indications for secreted frizzled-related protein 1 (sFRP1) inhibitors
  • Chemical compounds developed at Asahi Kasei Pharma will be provided at no cost. (Their structural information will not be disclosed.)
  • The characteristics of our compounds:
a )
Have approximately 50-fold higher sFRP1-inhibition activities, as compared with the commercially-available tool compound, WAY-316606.
b )
Can be administered orally.
  • High priority will be given to research projects that focus on the field of orthopedics, the medical field where Asahi Kasei Pharma directs its research and development efforts. (Proposals involving osteoporosis research will not be considered.)
8.2 Discovery of new indications for transient receptor potential ankyrin 1 (TRPA1) inhibitors in the field of orthopedics
  • A chemical compound developed at Asahi Kasei Pharma will be provided at no cost. (Its structural information will not be disclosed.)
  • The characteristics of our compound:
a )
Can inhibit both human and rat TRPA1 with an IC50 value at a few nanomolar.
b )
Can be administered orally.
  • Target indications should belong to the group of orthopedic disorders.
    (Proposals involving pain will not be considered.)

Subscription 

Click “Apply” to proceed to the application form.

pagetopボタン